Core Viewpoint - WuXi Biologics (02269) expects a revenue growth of approximately 16.7% to RMB 21.79 billion for the fiscal year 2025, driven by successful execution of its "Follow and Win" strategy and advanced technology platforms [1] Group 1: Financial Projections - Gross margin is anticipated to increase by about 5 percentage points to 46% [1] - Adjusted gross profit is projected to grow by 25.5% to approximately RMB 10.638 billion [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5.733 billion [1] - Adjusted net profit is forecasted to increase by about 22% to RMB 6.586 billion [1] Group 2: Strategic Initiatives - The revenue growth is attributed to the successful execution of the "Follow and Win" strategy, leading technology platforms, industry-best project delivery times, and excellent project execution track record [1] - WuXi Biologics' integrated CRDMO platform is set to add 209 comprehensive projects in 2025, bringing the total to a record high of 945 projects [1] Group 3: Additional Growth Drivers - Other factors contributing to performance growth include increased research service revenue from multiple advanced technologies [2] - Utilization of existing and new production capacities, including ramp-up at European production facilities [2] - Cost savings and efficiency improvements achieved through lean operational management systems and digital solutions [2] - Investment income gained through portfolio management [2]

Core Viewpoint - WuXi Biologics (02269) anticipates a revenue increase of approximately 16.7% year-on-year, reaching RMB 21.79 billion for the fiscal year ending December 31, 2025, alongside significant growth in profit margins and adjusted net profit [1][2] Group 1: Financial Projections - The company expects a gross margin improvement of about 5 percentage points to 46.0% [1] - Adjusted gross profit is projected to grow to approximately RMB 10.64 billion, representing a year-on-year increase of about 25.5% [1] - Profit attributable to equity shareholders is forecasted to rise by approximately 45.3% to RMB 5.73 billion, while net profit is expected to increase by about 46.3% to RMB 4.91 billion [1] - Adjusted net profit, accounting for stock-based compensation, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and related one-off costs, is anticipated to grow by approximately 22.0% to RMB 6.59 billion [1] Group 2: Growth Drivers - The growth is primarily driven by the successful execution of the "Follow and Win Molecule" strategy, leading to increased revenue through advanced technology platforms and industry-best project delivery times [2] - The company has expanded its service offerings in the biopharmaceutical sector, including research and discovery services, pre-IND development services, and clinical and commercial production services, particularly leveraging rapidly developing technology platforms like bispecific antibodies and ADCs [2] - Revenue growth from research services has been generated through multiple advanced technologies [2] - The utilization of existing and new production capacities, including ramp-up at European production facilities, has contributed to growth [2] - Cost savings and efficiency improvements have been achieved through the WuXi Biologics Lean Operations Management System (WBS) and digital solutions [2] - Investment income has been realized through the company's investment portfolio [2]

Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% year-on-year, reaching RMB 21,790 million for the fiscal year ending December 31, 2025 [1] Financial Performance - Gross margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is anticipated to grow to approximately RMB 10,638 million, representing a year-on-year increase of about 25.5% [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5,733 million [1] - Net profit, adjusted for share-based compensation, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and related one-off costs, is projected to increase by about 22.0% to RMB 6,586 million [1]

Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% year-on-year, reaching RMB 21,790 million for the fiscal year ending December 31, 2025 [1] Financial Performance - Gross margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is anticipated to grow to approximately RMB 10,638 million, representing a year-on-year increase of about 25.5% [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5,733 million [1] - Net profit, adjusted for share-based compensation expenses, foreign exchange gains and losses, equity investments, asset disposals, restructuring gains and losses, and related one-off costs, is projected to increase by about 22.0% to RMB 6,586 million [1]

Core Viewpoint - WuXi Biologics (02269) anticipates a revenue growth of approximately 16.7% year-on-year, reaching RMB 21.79 billion for the fiscal year ending December 31, 2025, alongside significant increases in profit margins and adjusted net profit [1][2] Group 1: Financial Projections - The company expects its gross profit margin to improve by about 5 percentage points to 46.0% [1] - Adjusted gross profit is projected to rise to approximately RMB 10.64 billion, reflecting a year-on-year growth of about 25.5% [1] - Profit attributable to equity shareholders is forecasted to increase by approximately 45.3% to RMB 5.73 billion, while net profit is expected to grow by about 46.3% to RMB 4.91 billion [1] - Adjusted net profit, after accounting for share-based compensation, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and related one-off costs, is anticipated to grow by about 22.0% to RMB 6.59 billion [1] Group 2: Growth Drivers - The growth is primarily driven by the successful execution of the "Follow and Win Molecule" strategy, leading to increased revenue through advanced technology platforms and industry-best project delivery times [2] - The company has expanded its service offerings in the biopharmaceutical sector, including research and discovery services, pre-IND development services, and clinical and commercial production services, leveraging rapidly developing technology platforms such as bispecific antibodies and ADCs [2] - Revenue growth from research services has been generated through multiple advanced technologies [2] - The utilization of existing and new production capacities, including ramp-up at European production facilities, has contributed to growth [2] - Cost savings and efficiency improvements have been achieved through the WuXi Biologics Lean Operations Management System (WBS) and digital solutions [2] - Investment income has been obtained through the company's investment portfolio [2]

Core Viewpoint - WuXi Biologics expects a revenue growth of approximately 16.7% year-on-year, reaching RMB 21,790 million for the fiscal year ending December 31, 2025 [1] Financial Performance - Gross margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is expected to rise to approximately RMB 10,638 million, reflecting a year-on-year growth of about 25.5% [1] - Profit attributable to equity shareholders is anticipated to grow by approximately 45.3% to RMB 5,733 million [1] - Net profit, adjusted for share-based compensation expenses, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and losses, and related one-off costs, is projected to increase by about 22.0% to RMB 6,586 million [1]

Core Viewpoint - WuXi Biologics (02269.HK) expects a revenue growth of approximately 16.7% to RMB 21.79 billion for the fiscal year ending December 31, 2025, driven by successful execution of its "Follow and Win" strategy and expansion of service offerings in the biopharmaceutical industry [1][2] Group 1: Financial Projections - The gross profit margin is projected to increase by about 5 percentage points to 46.0% [1] - Adjusted gross profit is expected to rise to approximately RMB 10.64 billion, reflecting a year-on-year growth of about 25.5% [1] - Profit attributable to equity shareholders is anticipated to grow by approximately 45.3% to RMB 5.73 billion, while net profit is expected to increase by about 46.3% to RMB 4.91 billion [1] - Adjusted net profit, after accounting for stock-based compensation, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and related one-time costs, is projected to grow by approximately 22.0% to RMB 6.59 billion [1] Group 2: Growth Drivers - Growth is primarily attributed to the successful execution of the "Follow and Win" strategy, leading to increased revenue from the group's advanced technology platforms and project execution [2] - The expansion of service offerings in the biopharmaceutical sector, including research and discovery services, pre-IND development services, and clinical and commercial production services, is a key factor [2] - Revenue growth from research services generated by multiple advanced technologies contributes to the overall financial performance [2] - Utilization of existing and new production capacities, including ramp-up at European production facilities, supports revenue growth [2] - Cost savings and efficiency improvements achieved through the WuXi Biologics Lean Operating Management System (WBS) and digital solutions are significant contributors [2] - Investment income from the company's investment portfolio also plays a role in the anticipated growth [2]

格隆汇2月11日丨药明生物(02269.HK)宣布，公司谨订于2026年3月24日(星期二)举行董事会会议，藉以 (其中包括)考虑及批准集团截至2025年12月31日止年度的全年业绩及其刊发。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI BIOLOGICS (CAYMAN) INC. 藥明生物技術有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2269） 香港，二零二六年二月十一日 於本公告日期，董事會成員包括執行董事陳智勝博士及Sherry Xuejun Gu博士；非執行董事 李革博士、曹彥凌先生及繆靜雯女士；及獨立非執行董事William Robert Keller先生、Kenneth Walton Hitchner III先生、戴國良先生及陳珏博士。 * 僅供識別 WuXi Biologics (Cayman) Inc.藥明生物技術有限公司*（「本公司」，連同其附屬公 司，統稱「本集團」）董事（「董事」）會（「董事會」）謹此宣佈，本公司謹訂於二零 二六年三月二十四日（星期二）舉行董事會會議，藉以（其中包括）考慮及批准 本集團截至二零二五年十二月三十一日止年度的全年業績及其刊發。 承董事會命 WuXi Biolo ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI BIOLOGICS (CAYMAN) INC. 本公司謹此知會本公司股東（「股東」）及潛在投資者，根據對本集團截至二零 二五年十二月三十一日止年度的未經審核綜合管理賬目（基於國際財務報告準 則(IFRS)編製）的初步評估，預期與去年同期比較，本公司截至二零二五年十二 月三十一日止全年度收益將增長約16.7%至人民幣21,790百萬元；毛利率將提升 約5個百分點至46.0%；經調整毛利將增長至約人民幣10,638百萬元，同比增長 約25.5%；本公司截至二零二五年十二月三十一日止全年度的利潤及歸屬於本 公司權益股東的利潤將分別增長約45.3%至人民幣5,733百萬元及約46.3%至人民 幣4,908百萬元；以及經調整以股份為基礎的薪酬開支、外匯損益、以及股權 投資、資產出售、重組損益及相關一次性成本後，本公司非國際財務報告準則 經調整純利將增長約22.0%至人民幣6,586百萬元。該等增長主要歸 ...